WuXi Biologics to Sell Irish Vaccine Assets to MSD for USD 500 Million
China-based Contract Research, Development and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) is poised to...
Junshi Biosciences’ Loqtorzi Gains Regular Approval for Melanoma Treatment in China
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877, SHA: 688180) has announced that its PD-1 inhibitor,...
Simcere Zaiming’s SIM0505 Receives NMPA Approval for Clinical Trials in Advanced Solid Tumors
China-based Simcere Pharmaceutical Group Limited’s (HKG: 2096) subsidiary, Simcere Zaiming, has announced that it has...
NMPA Releases 88th Batch of Reference Drugs for Generic Quality Consistency Evaluation
The National Medical Products Administration (NMPA) has released the 88th batch of reference drugs for...
Huahui Health’s HH-003 Gains Priority Review Status for Chronic Hepatitis D Treatment
The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has indicated...
WuXi Biologics and Candid Therapeutics Ink Global Research Agreement for Trispecific T-cell Engager
China-based Contract Research, Development and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced a...
Amoytop Biotech’s Pegfilgrastim Gains NMPA Approval for Preeclampsia Clinical Trials
Xiamen-based Amoytop Biotech Co. Ltd (SHA: 688278) has announced that it has received clinical trial...
Hengrui Pharmaceuticals Files IPO Prospectus in Hong Kong Amid Record Deal-Making
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has officially submitted an initial public offering (IPO)...
Changchun BCHT Partners with Baosight Software for Biopharmaceutical Digitization
China-based Changchun BCHT Biotechnology Co., Ltd (SHA: 688276) has announced a partnership with compatriot firm...
CDE Announces 90th Batch of Reference Preparations for GQCE
China’s Center for Drug Evaluation (CDE) has selected the 90th batch of reference preparations for...
Solasia Pharma Licenses Episil to GeneScience for Greater China Region
Japan-based Solasia Pharma K. K (TYO: 4597) has announced a licensing agreement with Changchun GeneScience...
Alebund Pharmaceuticals Completes Series C Financing to Advance Kidney Disease Pipelines
Shanghai-based Alebund Pharmaceuticals has announced the completion of a Series C financing round, raising RMB...
GSK’s Nucala Receives New Indication Approval in China for CRSwNP
UK-based pharmaceutical company GlaxoSmithKline’s (GSK; NYSE: GSK) has announced that it has received another indication...
China’s Healthcare Bureaus Remove Drug Quantity Limits to Enhance NRDL Access
The healthcare security administration bureaus in Shanghai, Beijing, and other regions have recently removed limits...
Kexing Pharmaceutical Partners with Shandong Boan for Biosimilar Commercialization in Hong Kong and Macau
China-based Kexing Pharmaceutical (SHA: 688136) has entered into a commercialization cooperation agreement with fellow Chinese...
Shengwei Kunteng Raises RMB 200 Million in Series A Financing for POCT Development
China-based Hunan Shengwei Kunteng Biotechnology Co., Ltd has announced that it has raised close to...
Hangzhou Highlightll Pharma Completes Pre-Series C Financing Round
China-based Hangzhou Highlightll Pharmaceutical Co., Ltd has announced the successful completion of a Pre-Series C...
Aosaikang’s Generic Livtencity Accepted for Review by China’s NMPA
China’s Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has revealed that a market filing for...
Sinobioway Medicine Partners with Happy Life Tech for Clinical Trial Services
China-based Contract Manufacturing Organization (CMO) Sinobioway Medicine (SHE: 002581) has announced a clinical trial technical...
Balance Medtech’s Interventional Pulmonary Valve Receives Fast-Track Designation from NMPA
China’s Beijing Balance Medical Technology Co., Ltd. (SHA: 688198) has announced that it has received...